Subject to approval by an EGM, the merger is expected to accelerate Serodus’ commercialisation and development strategy with the addition of two first-in-class drug candidates SER130 and SER140.
SER130 is an IL-4 partial receptor agonist for Acute Myocardial Infarction (AMI) and SER140 is an IL-1 receptor antagonist for Type 2 diabetes.
Serodus CEO Eva Steines said," Phlogo’s peptides SER130 and SER140 come from internationally-recognized researchers at Copenhagen University who have been concentrating on mimicking and inhibiting endogenous inflammatory cascades."
SER130 focuses on the severe tissue damage, which occurs after a heart attack, and SER140 is an anti-inflammatory drug candidate targeted at diabetes.
Phlogo CEO Torben Skarsfeldt said, "Phlogo has generated very interesting data on both compounds, but we were in a position where the company needed additional resources to continue the development."